Worldwide Healthcare Trust H1 2026 results impress with 14.8% total return (LON: WWH)

Worldwide Healthcare Trust

Worldwide Healthcare Trust PLC (LON:WWH) has announced its Unaudited Results for the Six Months ended 30 September 2026

The statements below are extracted from the Company’s half-year report for the six months ended 30 September 2026. This announcement contains references to graphs and charts which appear in the full Half Year Report, which will shortly be available on the Company’s website: www.worldwidewh.com where up to date information on the Company, including daily NAV, share prices and fact sheets, can also be found.

The Half Year Report has been submitted to the Financial Conduct Authority, and will shortly be available for inspection on the National Storage Mechanism (NSM) at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

Performance

  SIX MONTHS TOONE YEAR TO
  30 SEPTEMBER31 MARCH
  20262026
Net asset value per share (total return)* # +9.3%+10.0%
Share price (total return)* # +14.8%+13.1%
Benchmark (total return)^ # +9.9%+1.8%
 30 SEPTEMBER31 MARCHSIX MONTHS
 20262026CHANGE
Net asset value per share403.6p371.0p+8.8%
Share price381.5p334.0p+14.2%
Discount of share price to the net asset value per share(5.5)%(10.0)% 
Leverage114.9%12.5% 
Ongoing charges*0.9%0.9% 
Ongoing charges (including performance fees crystallised during the period)*0.9%0.9% 

# Source – Morningstar.

^ Benchmark – MSCI World Health Care Index on a net total return, sterling adjusted basis (see Glossary).

* Alternative Performance Measure (See Glossary).

1 Leverage calculated under the Commitment Method (see Glossary).

Statement from the Chair

“During the first half of the financial year, the Company’s net asset value per share total return was +9.3% and the share price total return was +14.8%, these compared to a return of +9.9% from the Company’s Benchmark.”

This is my first statement to shareholders of Worldwide Healthcare Trust PLC following my appointment as Chair at the conclusion of the Company’s Annual General Meeting (“AGM”) in July 2026. I am pleased to report that, against a backdrop of ongoing economic and geopolitical uncertainty, the Healthcare sector’s long-term fundamentals remain compelling. Innovation across Pharmaceuticals, Biotechnology and Healthcare Services continues to create attractive opportunities for active investors. While market sentiment towards Healthcare stocks remained variable during the period, the Board remains confident in the Company’s investment approach and long-term prospects.

PERFORMANCE

During the six-month period, global markets continued to be influenced by the evolving macroeconomic environment, the trajectory of interest rates, geopolitical developments and the ongoing impact of artificial intelligence-related investment. Whilst broader equity markets remained supported by resilient economic activity and generally healthy corporate earnings, investor sentiment continued to fluctuate in response to policy developments and concerns regarding economic growth in several major regions.

Against this backdrop, the performance of the Healthcare sector, which underperformed the broader market in the period, reflected a combination of policy, regulatory and company-specific factors. While the sector continued to benefit from strong levels of innovation, particularly in Biotechnology and precision medicine, investor attention (particularly in the first few months of the financial year) remained focused on issues such as drug pricing and the pace of regulatory approvals. Merger and acquisition activity remained an important feature of the Healthcare landscape, providing support for valuations across selected areas of the market.

In this environment, I am pleased to report that the Company’s net asset value (“NAV”) per share total return during the six months to 30 September 2026 was +9.3%, and the share price total return was 14.8%, these compared to a net total return of +9.9% from the Company’s Benchmark, the MSCI World Health Care Index (sterling-adjusted), during the same period. The discount of the Company’s share price to the NAV per share discount moved from 10.0% to 5.5% during the half year.

The Portfolio Manager continued to identify attractive opportunities across Healthcare subsectors and geographies while also maintaining the Company’s long-standing emphasis on innovation, scientific advancement and long-term growth potential.

Looking at specific names in the portfolio, the top two contributions came from U.S. Pharmaceutical major EliLilly and U.S. Biotechnology company Natera. Theportfolio’s proprietary swap basket of Biotechnology companies with the potential to be acquired also made a positive contribution to performance during the period. Meanwhile, the two principal detractors from performance were U.S. Medical Technology company Boston Scientific and Swedish-British multinational Pharmaceutical and Biotechnology company AstraZeneca. Further information on the Company’s investments and performance can be found in the Portfolio Manager’s Review.

As shareholders will be aware, leverage remains an important component of the Company’s investment approach. Average leverage during the period was 14.9%, contributing 1.1% to overall performance. At the half-year end, leverage stood at 14.9%, compared with 12.5% at the start of the period.

PERFORMANCE FEE

No performance fee was accrued as at 30 September 2026 and no performance fee can become payable within the next year. The performance fee arrangements are described in detail in the Company’s Annual Report.

CAPITAL

Share price discounts continued to be a prominent feature of the investment company sector during the period. As noted above, the Company’s discount to NAV stood at 5.5% on 30 September 2026, this compares to an average share price discount in the sector of 11.8%. (source: Winterflood Investment Trusts).

The Board’s policy remains to repurchase shares when the Company’s discount to NAV exceeds 6% on an ongoing basis. Despite the Company’s share buybacks, the discount can remain greater than 6% for extended periods of time, depending on overall sentiment towards the Company, the sector and investment companies generally. Whilst share buybacks cannot entirely offset wider market sentiment towards investment companies, they enhance NAV per share for continuing shareholders and remain an important mechanism in the management of the discount.

During the period, the Company repurchased a total of 31,330,075 shares for treasury at a cost of £115.9m and at an average discount of 7.2%. At the period end, there were 342,082,342 shares in issue (excluding the 259,582,858 shares held in treasury). From the period end to 16 November 2026, a further 7,776,867 shares have been bought back for treasury, at a cost of £30.0m and at an average discount of 7.5%.

The Board remains committed to its discount control policy and will continue to monitor market conditions closely while balancing the interests of both existing and prospective shareholders.

The Company’s share buyback authority will, as usual, be proposed for renewal at the Company’s AGM to be held on Tuesday,13 July 2027.

DIVIDENDS

The Board has declared an unchanged interim dividend of 0.7p per share, for the year to 31 March 2027. It will be payable on 8 January 2027 to shareholders on the register of members on 27 November 2026, with an ex-dividend date of 26 November 2026.

The Board continues to believe that shareholders’ long-term interests are best served by maximising opportunities for capital growth through investment in the portfolio rather than targeting a particular dividend yield. Accordingly, the Company’s dividend policy remains focused on maintaining investment trust status and distributing income in accordance with applicable requirements.

COMPOSITION OF THE BOARD AND PORTFOLIO MANAGEMENT RESPONSIBILITIES

As I have mentioned, I succeeded Doug McCutcheon as Chair of the Board when he retired from the Board at the conclusion of the AGM in July. On behalf of the Board and Shareholders, I would like to thank Doug for his leadership, commitment and the hugely valuable contribution he made to the Company throughout his tenure.

We also announced, in August, that Sven Borho was stepping down as the Company’s lead portfolio manager, and he retired from the Board on 30 October 2026. Sven was involved in the growth and strategy of the Company since its inception in 1995 and served as a Director for the last eight years. On behalf of the Board, I would like to express gratitude to Sven for his significant efforts on behalf of the Company throughout that time.

We shall miss the contributions of Doug and Sven, both in Board meetings, and outside.

We were, however, delighted that Trevor Polischuk, who was previously co-portfolio manager with Sven, agreed to take on the role of lead portfolio manager in August and we announced the appointment of Geoff Hsu as his co-portfolio manager at the same time. Trevor and Geoff both know the Company’s portfolio well and the Company’s investment approach has not changed as a result of Sven’s retirement.

OUTLOOK

The Board remains confident in the long-term investment case for the global Healthcare sector.

Healthcare continues to benefit from powerful structural growth drivers, including ageing populations, rising Healthcare expenditure, increasing demand for innovative therapies and rapid advances in medical science and technology. In addition, the pace of innovation across areas such as oncology, obesity treatments, precision medicine and artificial intelligence-enabled Healthcare remains compelling.

Whilst periods of market volatility are likely to persist, the Board believes that current valuations across parts of the Healthcare sector continue to present attractive opportunities for active investors. We therefore remain confident in the Portfolio Manager’s ability to generate attractive long-term returns through disciplined stock selection and effective capital allocation.

As I begin my tenure as Chair, I do so with confidence in the Company’s strategy, the strength and depth of its portfolio, and the expertise of the Portfolio Manager, all set against this positive backdrop for the Healthcare sector.

I look forward to engaging with shareholders in the years ahead and thank you for your continued support of the Company.

William Hemmings

Chair

17 November 2026

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Worldwide Healthcare Trust H1 2026 results impress with 14.8% total return (LON: WWH)

Worldwide Healthcare Trust has reported a 9.3% NAV total return and a 14.8% share price total return for the...

Worldwide Healthcare Trust reports 10.0% NAV total return for FY2026

Worldwide Healthcare Trust PLC reported a 10.0% net asset value total return for the year ended 31 March 2026,...

Worldwide Healthcare Trust gains 20% in 2025, highly bullish for 2026 (LON: WWH)

Worldwide Healthcare Trust reports December performance, key contributors and detractors, and outlines expectations for healthcare in 2026, including policy,...

Worldwide Healthcare Trust reports -10.3% NAV return for FY25

Worldwide Healthcare Trust PLC (LON:WWH) has released its Annual Financial Report for the year ending March 31, 2025, highlighting...

Worldwide Healthcare Trust Plc outperforms benchmark in H1 results

Worldwide Healthcare Trust PLC (LON:WWH) outperformed its benchmark in the half-year results ending 30 September 2024, recording notable returns....

Worldwide Healthcare Trust PLC publishes Annual Financial Report

Discover the latest financial performance of Worldwide Healthcare Trust PLC in their Annual Report for the year ended 31...

    Search